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The Kidd-null phenotype, Jk(a–b–), is rare, and a patient with 
this phenotype may develop anti-Jk3, a red blood cell (RBC) 
antibody reactive with a domain common to both Jka and Jkb. Like 
other antibodies to high-prevalence antigens, the presence of this 
antibody poses challenges in the immunohematologic evaluation 
of these patients. Thoughtful laboratory testing is necessary to 
resolve the antibody specificity and to reveal other underlying 
antibodies. Moreover, the rarity of the Kidd-null phenotype makes 
finding blood donors difficult for those who need transfusion and 
have developed anti-Jk3. This review describes methods used 
in identifying anti-Jk3 in four pregnant patients. Blood bank 
records were retrospectively reviewed to illustrate the common 
approach in anti-Jk3 identification. In all cases, pertinent blood 
bank history was gathered, and extended RBC phenotyping was 
performed, followed by adsorption studies and testing of selected 
RBCs. Underlying antibodies were found in two of the cases. This 
review also reiterates some common challenges encountered 
with Kidd antibody analysis and highlights the importance 
of patient ethnic ancestry and obtaining accurate patient 
transfusion history. Immunohematology 2021;37:84–88. 
DOI:10.21307/immunohematology-2021-013.
Key Words: anti-Jk3, alloantibody, ethnicity
Identifying an antibody against a high-prevalence antigen 
is a challenging aspect of transfusion medicine. To narrow 
the possible cause of reactivity, knowledge of the patient’s 
ethnicity, transfusion history, and pregnancy history are key 
elements.1 Moreover, known properties of the antibody such as 
common phase of reactivity and reactivity against chemical- 
and enzyme-treated red blood cells (RBCs) as well as the 
availability of rare RBCs are important factors used to identify 
the antibody.1 In addition, testing the patient’s RBCs using 
antisera to high-prevalence antigens and RBC genotyping can 
aid in confirming the antibody specificity.1
Some antibodies to high-prevalence antigens may be 
suspected based on the patient’s ethnicity, such as anti-Fy3, 
anti-U, and anti-Jsb among individuals of African descent; 
anti-Kpb and anti-k among individuals of European descent; 
anti-H among individuals from the Indian subcontinent; anti-
Dib among those of Asian, South American Indian, and Native 
American descent; and anti-Jk3 among individuals of Finnish, 
Asian, and Polynesian descent.1,2
The Kidd system was first described in the 1950s, and there 
are currently four known phenotypes: Jk(a–b+), Jk(a+b–), 
Jk(a+b+), and Jk(a–b–).3 The Jk(a–b–) phenotype was first 
described by Pinkerton et al.4 in a Filipina individual in 1959. 
Jk(a–b–) is uncommon among individuals of European 
descent (p < 0.01) and is more common among individuals 
of Finnish, Asian, and Polynesian descent.1,2,3,5 Antibodies in 
this system are known to cause acute and delayed transfusion 
reactions, but only rarely cause severe hemolytic disease 
of the fetus and newborn (HDFN).3,5 They are usually of 
immunoglobulin (Ig)G1 and IgG3 types and often cause 
hemolysis by activating complement.3,5 Anti-Jk3 reacts with 
all Kidd phenotypes except Jk(a–b–).3,5 This report presents 
four cases of pregnant women who developed anti-Jk3.
Case Presentation
Case 1
A 27-year-old G3P2 Polynesian woman, with a history 
of transfusion 1 year previously, presented for prenatal care. 
Her sample was referred to the American Red Cross Reference 
Laboratory for antibody identification. The patient’s plasma 
reacted with all RBCs tested in polyethylene glycol (PEG) by 
the indirect antiglobulin test (IAT); however, the autocontrol 
and her polyspecific direct antiglobulin test (DAT) were 
negative. Blood typing and extended phenotyping were also 
performed. Her RBCs tested as group A, D+C+E–c–e+; K–; 
Fy(a+b–); Jk(a–b–); Le(a+b–); P1+; and M+N+S–s+. Based on 
the reactivity of her plasma in conjunction with her Jk(a–b–) 
phenotype, anti-Jk3 was suspected. The laboratory then 
tested her plasma against rare Jk(a–b–) RBCs. These RBCs 
were nonreactive with the patient’s plasma. To determine if 
there were any underlying antibodies, warm adsorptions with 
papain-treated, phenotypically similar RBCs were performed. 
Two sets of adsorptions were performed: one with Jk(a–) 
RBCs and one with Jk(b–) RBCs. The plasma adsorbed with 
the Jk(a–) RBCs revealed an underlying anti-Jka. All other 
common clinically significant antibodies were ruled out using 
Jk(a–b–) RBCs, adsorbed plasma, and the patient’s phenotype. 
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Antibody titration using Jk(a+b+) RBCs was also performed. 
The combined titer of anti-Jka and anti-Jk3 was 16 with a 
score of 45. The sample was not sent for RBC genotyping.
Case 2
A 24-year-old G3P2 woman of unknown ethnicity 
was admitted for delivery. Her transfusion history was also 
unknown. The patient’s plasma reacted with all RBCs tested, 
which prompted the hospital to send a sample to the American 
Red Cross Reference Laboratory for evaluation. Testing 
revealed the patient’s RBCs to be group A, D+C+E–c–e+; K–; 
Fy(a+b–); Jk(a–b–); Le(a+b–); and M+N–S–s+. The patient’s 
plasma reacted w+ to 1+ in low-ionic-strength saline (LISS)-
IAT and 1+ to 2+ in PEG-IAT. The autocontrol was nonreactive, 
and the polyspecific DAT was negative. Anti-Jk3 was suspected 
based on the patient’s Jk(a–b–) phenotype and the reactivity 
observed in her plasma. Her plasma was then tested against 
Jk(a–b–) RBCs from the laboratory’s frozen inventory and 
found nonreactive, which confirmed the presence of anti-Jk3. 
To further evaluate for other alloantibodies, warm adsorptions 
with phenotypically similar papain-treated RBCs were 
performed to remove the anti-Jk3. The laboratory used Jk(a–
b+) adsorbing RBCs and tested the adsorbed plasma with 
selected Jk(a–b+) RBCs. Other common clinically significant 
antibodies were ruled out using the adsorbed plasma and the 
patient’s phenotype. The presence of separable anti-Jka and 
anti-Jkb was not evaluated in this case. Antibody titration and 
RBC genotyping were not performed.
Case 3
Reactivity with all RBCs was observed in the testing 
of the plasma of a 33-year-old Asian G2P1 woman at 39 
weeks’ age of gestation on her prenatal care visit. The sample 
was then submitted to the American Red Cross Reference 
Laboratory for further evaluation. The patient had never 
been transfused, and her hemoglobin (Hgb) at that visit was 
12.2 g/dL (normal range 11.1–15.9 g/dL). Similar to the 
cases described earlier, the autocontrol was nonreactive, and 
the DATs tested by gel and tube methods using polyspecific 
antihuman globulin (AHG) were negative. This reactivity 
pointed to a possible antibody to a high-prevalence antigen. To 
gain further information in the investigation, the patient’s blood 
type and extended phenotype were determined. Her RBCs 
tested as group A, D+C+E+c+e+; K–; Fy(a+b–); Jk(a–b–); and 
S–s+. The reference laboratory concluded that it was a probable 
anti-Jk3 based on the patient’s Jk(a–b–) phenotype and 
ethnicity. The reference laboratory did not have Jk(a–b–) RBCs 
available to further confirm the specificity, and the antibody 
was thus identified as “probable anti-Jk3.” To facilitate the 
removal of the probable anti-Jk3 to allow for further antibody 
exclusions, warm adsorptions were performed. Two sets of 
papain-treated RBC stroma were used: R1R1; K–; Jk(a–), and 
R2R2; K–; Jk(b–). No underlying antibodies were observed 
in the adsorbed plasma. The patient’s sample was sent for 
molecular testing, which revealed a genotype of JK*02N.01/
JK*02N.01 with a predicted phenotype of Jk(a–b–).
Case 4
A 35-year-old G1P0 Asian woman was admitted for 
induction of labor. The patient’s transfusion history was 
unknown, and her Hgb was 4.4 g/dL (normal reference range 
unknown) at the time of admission. Evaluation of the patient 
was referred to the American Red Cross Reference Laboratory 
because of panreactivity by the IAT with a nonreactive 
autocontrol. Further testing revealed the patient’s RBCs had 
a negative DAT (gel/IgG and tube/polyspecific AHG) and 
tested as group A, D+C+E–c–e+; K–; Fy(a+b–); Jk(a–b–); 
and S–s+. Based on the patient’s Jk(a–b–) phenotype and 
plasma reactivity, anti-Jk3 was suspected, but the plasma 
was reactive with two group O rr Jk(a–b–) RBCs. The plasma 
was also differentially warm adsorbed with R1R1 Jk(a–b+), 
R2R2 Jk(a–b+), and rr Jk(a+b–) papain-treated RBC stroma 
to remove the anti-Jk3. Warm adsorptions revealed anti-
Jkb in the adsorbed plasma using the gel method. Because of 
reactivity with Jk(a–b–) RBCs, the sample was sent to another 
reference laboratory for further investigation. The second 
reference laboratory found four additional Jk(a–b–) RBCs 
nonreactive with the patient’s plasma by LISS-IAT and PEG-
IAT techniques. Because the patient’s RBCs tested as R1R1 
and had reactivity with rr Jk(a–b–), anti-c was suspected but 
ruled out when the R1R1-adsorbed plasma tested against R2R2 
RBCs was nonreactive; a probable anti-f was then identified. 
Not all common alloantibodies could be excluded using the 
Jk(a–b–) RBCs, and, thus, differential adsorption studies with 
ZZAP (DTT-ficin)-modified allogeneic RBCs were performed 
to intentionally adsorb out the anti-Jk3. The adsorbed plasma 
revealed anti-Jka and anti-Jkb by LISS-IAT. Lastly, the 
second reference laboratory also identified an anti-P1 at room 
temperature with some reactivity carried through the IAT. 
The patient's plasma reacted with most P1+ Jk(a–b–) RBCs at 
room temperature but was nonreactive at 37°C and by the IAT 
using a strict prewarm technique.
Identifying anti-Jk3
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Materials and Methods
In all cases, antibody identification was performed using 
PEG-IAT, and DATs were performed in tube using polyspecific 
AHG. In addition, case 2 was tested in LISS-IAT, case 3 was 
tested using IgG ID-MTS Gel (Ortho Clinical Diagnostics, 
Raritan, NJ), and case 4 was tested using IgG ID-MTS Gel 
(Ortho Clinical Diagnostics) and LISS-IAT. Additional DATs 
in cases 3 and 4 were performed using IgG ID-MTS Gel. 
The titration performed in case 1 was tested in saline-IAT 
for 30 minutes. A Precise Type HEA Molecular BeadChip kit 
(Immucor, Norcross, GA) was used to perform the molecular 
testing in case 3. Adsorption studies in cases 1 and 2 used 
papain-treated, allogeneic, phenotypically similar RBCs, and 
cases 3 and 4 used papain-treated, allogeneic RBC stroma. 
Additional adsorption studies performed in case 4 used ZZAP 
(DTT-ficin)-treated allogeneic RBCs.
Discussion
Kidd antibodies are immunogenic and notoriously known 
to weakly react by the IAT.3,5 Although strong reactivity 
with test RBCs can be seen, it is not uncommon to find 
Kidd antibodies reacting more strongly with RBCs carrying 
a double dose of Jka or Jkb than with single-dose antigen-
positive RBCs.3 Using enzyme-treated RBCs can strengthen 
the reactivity of Kidd antibodies.3,5 The possible cause of weak 
reactivity of the Kidd antibody in the methods used is that 
most test modalities now use plasma for testing and anti-IgG 
in the IAT. Kidd antibodies can react more strongly when using 
polyspecific AHG containing anti-C3.3 In addition, it is known 
that Kidd antibody titers quickly decline, and the antibody 
can become serologically non-demonstrable a few weeks to 
months after initial identification.3,5 Because of their unreliable 
detectability in vitro, it is not surprising that Kidd antibodies 
are a common cause of delayed hemolytic transfusion 
reactions.3,5 It is therefore important to inform patients about 
their immunization to Kidd antigens and encourage them to 
mention this as part of their past medical history, especially if 
blood transfusion is indicated.
Antibodies to high-prevalence antigens typically present 
with panreactivity of equal strength, a nonreactive autocontrol, 
and a negative DAT.1 This typical reactivity was seen in all four 
cases described herein, but it is also possible for antibodies 
to high-prevalence antigens to present with a positive DAT 
and/or autocontrol when other clinical scenarios are present. 
A case reported by McCaskill et al.6 described a Filipino man 
with chronic obstructive pulmonary disease, hypertension, 
hyperlipidemia, and drug-induced hepatitis whose plasma 
reacted with all test RBCs including his autocontrol. The 
patient’s DAT was also positive. After further testing, it was 
concluded that the patient had anti-Jk3, and the positive DAT 
was possibly due to his recent transfusion.6
The initial approach in all four cases was to determine 
the extended phenotype and gather pertinent blood bank 
information about the patient. Table 1 contains a summary 
of the patients’ blood bank history and the laboratory results 
pertinent to these case studies.
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Table 1. Summary of pertinent patient blood bank history and laboratory results
Parameter Case 1 Case 2 Case 3 Case 4
Ethnicity Polynesian Unknown Asian Asian
Transfusion history 1 year ago Unknown Never been transfused Unknown
Obstetric score G3P2 G3P2 G2P1 G1P0
Known RBC antibodies None None None None
Hemoglobin (g/dL) Unknown Unknown 12.2 4.4
ABO/D A, D+ A, D+ A, D+ A , D+
Extended phenotype R1R1; K–; Fy(a+b–);  
Jk(a–b–); M+ N+ S– s+
R1R1; K–; Fy(a+b–);  
Jk(a–b–); M+ N– S– s+
R1R2; K–; Fy(a+b–);  
Jk(a–b–); S– s+
R1R1; K–; Fy(a+b–);  
Jk(a–b–); S– s+
DAT Negative Negative Negative Negative
Antibody identification Anti-Jk3, anti-Jka Anti-Jk3 Probable anti-Jk3 Anti-Jk3, anti-Jka, anti-Jkb, 
probable anti-f, anti-P1
Titer 16 Not performed Not performed Not performed
RBC genotyping Not performed Not performed JK*02N.01/JK*02N.01 Not performed
RBC = red blood cell; DAT = direct antiglobulin test.
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Identifying anti-Jk3
All patients demonstrated a Kidd-null phenotype, 
Jk(a–b–), and therefore were suspected to have anti-Jk3. To 
confirm the presence of anti-Jk3, the plasmas in all cases 
except case 3 were tested with rare Jk(a–b–) RBCs and 
found to be nonreactive. To facilitate removal of the anti-Jk3, 
adsorption studies were performed in all cases. Cases 2 and 
3 had no underlying antibodies, whereas case 1 was found 
to have an underlying anti-Jka, and case 4 had underlying 
probable anti-f, anti-Jka, anti-Jkb, and anti-P1. Only the sample 
in case 3 was sent for RBC genotyping.
Titration studies with RBCs carrying a single-dose anti-
gen were performed in case 1. HDFN due to Kidd antibodies 
is often mild and may be because newborns have fewer 
complement components compared with adults and therefore 
less complement interaction with the antibodies.3 A case study 
by Lawicki et al.7 described the clinical severity of HDFN in 
four cases of pregnant women with alloanti-Jk3. In two of the 
cases, the HDFN was of mild to moderate severity, while the 
other two had no clinically significant HDFN.7 The case of 
moderate HDFN severity had a maximum anti-Jk3 titer of 128. 
However, one of the clinically insignificant cases had a higher 
titer compared with that of the mildly severe HDFN case (32 
vs. 16).7 This study further established that the significance of 
anti-Jk3 titer remains unclear. Moreover, because of a lack of 
data in the literature that correlate anti-Jk3 titers and severity 
of HDFN, it is reasonable to monitor pregnant patients who 
develop anti-Jk3 for possible HDFN.7
In case 2, anti-Jka and anti-Jkb were not ruled out. It is not 
necessary to rule out the related specificities in patients with 
an antibody against the high-prevalence antigen lacking in a 
null phenotype. Moreover, the transfusion recommendation 
is not dependent on whether these antibodies are present. 
Case 3 was evaluated in a reference laboratory that did not 
have rare RBCs lacking high-prevalence antigens available 
for testing. The presence of anti-Jk3 was not confirmed by 
demonstrating her plasma was nonreactive with Jknull RBCs 
and was therefore called probable anti-Jk3. The antibody 
specificity was based on the plasma reactivity and patient’s 
phenotype. The alleles found in the genotyping in this case are 
seen among individuals of Polynesian descent. There is a splice 
site mutation in intron 4 of the null allele that results in an 
absence of the JK protein from the membrane.8
Removal of anti-Jk3 by adsorption using either Jk(a+b–), 
Jk(a–b+), or Jk(a+b+) RBCs or RBC stroma was performed 
to evaluate other concomitant antibodies possibly present 
with the anti-Jk3. Case 4 is a good example of anti-Jk3 with 
underlying antibodies. Despite the suspicion of anti-Jk3, the 
initial testing with Jk(a–b–) RBCs was positive. This finding 
indicated that another antibody may be present or that the 
reaction may not be due to anti-Jk3. Looking closely at the rare 
RBCs tested in the initial reference laboratory revealed that 
the two Jk(a–b–) RBCs used were group O, rr (C–E–c+e+f+). 
f is a compound antigen expressing c and e in cis formation. 
f is absent when c and e are found on two different proteins 
(trans position) such as R1R2 (DCe/DcE) or when c and e are 
not seen together such as R1R1 (DCe/DCe) or R2R2 (DcE/
DcE).9 Based on the patient’s phenotype in case 4, her RBCs 
are f–, and thus she can develop anti-f. Because of multiple 
unexpected reactivities and lack of additional rare Jk(a–b–) 
RBCs to confirm anti-Jk3, another sample was collected and 
referred to a second reference laboratory. This laboratory 
tested four Jk(a–b–) RBCs. These RBCs were nonreactive, 
which confirmed the presence of anti-Jk3. They also found 
that anti-Jka and anti-Jkb were present after removing anti-
Jk3 by adsorption. It is worth mentioning that anti-Jka was 
not detected by the initial reference laboratory, and this is most 
likely due to the known variable reactivity of Kidd antibodies in 
vitro and the possibility of these antibodies being undetected 
when using IgG ID-MTS Gel. In 1996, a study by de Castilho 
et al.10 compared the sensitivity of serologic methods in 
detection of antibodies. They found that in reference samples, 
PEG-IAT was the most sensitive method for detection of Kidd 
antibodies. However, in the same study, it was found that 
gel LISS testing was a more sensitive modality in detecting 
antibodies for routine samples. Another study done by Kay et 
al.11 concluded that solid-phase red cell adherence (SPRCA) 
was more sensitive in detecting Kidd antibodies than IgG 
ID-MTS Gel. They noted a statistically significant increase in 
rate of anti-Jka detection from 5.4 to 11.86 per 10,000 solid-
phase antibody screens performed when they switched from 
IgG ID-MTS Gel to SPRCA as a primary method for antibody 
screening. Considering that Kidd antibodies are more easily 
detected in PEG-IAT or LISS-IAT, the second reference 
laboratory was most likely to detect the anti-Jka because they 
used LISS-IAT when testing their adsorbed plasma.
Although none of the cases used the urea lysis test, 
this laboratory test can aid in identification of the Jk(a–b–) 
phenotype, particularly in large-scale donor testing.6 The Jknull 
phenotype is known to be resistant to urea-induced lysis.3,5,6,12 
RBCs with other Kidd phenotypes will lyse in the presence of 
2 M urea.6,12
The patients in this report did not require RBC transfu-
sions. The clinical status and hematocrit of these patients 
remained stable throughout their hospital stay.
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Conclusion
A high-prevalence antigen is an antigen present in almost 
all populations, and its absence is considered rare (<1:1000).1 
This fact makes finding blood for a patient who develops an 
antibody against a high-prevalence antigen difficult. Stable 
healthy patients who have an antibody to a high-prevalence 
antigen are encouraged to donate autologous units.1,7 If the 
condition of the patient does not allow this type of donation, 
testing their family members for the phenotype needed is 
another option.1,7 In addition, the American Rare Donor 
Program is a network used by reference laboratories to aid in 
finding rare blood units.1,7
Anti-Jk3 is an example of an antibody against a high-
prevalence antigen. Because of the continuous growth and 
diversity of the U.S. population, it is important to remember 
its prevalence among certain ethnicities. Donor recruitment 
geared towards individuals in these ethnic populations can 
increase the inventory of Jknull RBC units.
When dealing with reactivity consistent with an antibody 
to a high-prevalence antigen, obtaining history regarding 
transfusion, pregnancy, and patient’s ethnicity are the first 
steps to narrowing the possible cause of reactivity.1 Therefore, 
obtaining an accurate and complete blood bank history is of 
utmost importance.3 An extended phenotype including high-
prevalence antigens that are commonly lacking in individuals 
in the ethnic group of the patient is helpful in further narrowing 
the possible cause of reactivity.1 Testing RBCs after enzyme 
treatment with papain or ficin, chemical treatment with DTT 
or EDTA glycine acid, and adsorption studies can also help 
pinpoint the specificity of the antibody.1 By carefully analyzing 
the pattern of reactivity observed, selected rare RBCs can then 
be tested to confirm the presence of the antibody.
Acknowledgments
We would like to extend our appreciation to Leslie Thomas, 
Jessica Kosarek, Rebecca Robison, and Chanthanymul 
Bunleang for reviewing this case study for accuracy of 
description of the cases and their discussion, and we thank 
Dana Smith for her technical writing assistance.
References
 1. Er LS, Bailey DJ. Identification of antibodies to red cell antigens. 
In: Cohn C, Delaney M, Johnson S, Katz L, Eds. Technical 
manual. 20th ed. Bethesda, MD: AABB Press, 2020:410–3, 
423–4.
 2. Yousuf R, Suria AA, Nurasyikin Y, Leong C. A rare case of anti-
Jk3 antibody detected on pre-transfusion investigation. Indian 
J Hematol Blood Transfus 2014;30:208–10.
 3. Issitt PD, Anstee DJ. Applied blood group serology. 4th ed. 
Montgomery Scientific Publications, 1998:655–68.
 4. Pinkerton FJ, Mermod LE, Liles BA, et al. The phenotype 
Jk(a–b–) in the Kidd blood group system. Vox Sang 
1959;4:155–60.
 5. Melland C, Nance S. Other blood group systems and antigens. 
In: Cohn C, Delaney M, Johnson S, Katz L, Eds. Technical 
manual. 20th ed. Bethesda, MD: AABB Press, 2020:370–2.
 6. McCaskill S, Wise S, Tinsley S. Anti-Jk3 in a Filipino man. 
Immunohematology 2015;31:119–22.
 7. Lawicki S, Coberly EA, Lee LA. Jk3 alloantibodies during 
pregnancy-blood bank management and hemolytic disease of 
the fetus and newborn risk. Transfusion 2018;58:1157–62.
 8. International Society of Blood Transfusion. Names for JK 
(ISBT 009) blood group alleles. Available from http://www.
isbtweb.org/fileadmin/user_upload/_ISBT_009__ JK_
blood_group_alleles_v6.0_01-MAR-2020.pdf. Accessed 03 
October 2020.
 9. Reid ME, Lomas-Francis C, Olsson ML. The blood group 
antigen factsbook. 3rd ed. Philadelphia, PA: Elsevier, 2012: 
210–1, 377.
 10. de Castilho LM, Pellegrino J Jr, Bechelli APP, Le Pennec PY, 
Mendres N. Evaluation of recent techniques for detection 
of red blood cell antibodies in sera of reference samples, 
patients, pregnant women, and blood donors. J Clin Lab Anal 
1996;10:250–6. 
 11. Kay B, Poisson JL, Tuma CW, Shulman IA. Anti-Jka that are 
detected by solid-phase red blood cell adherence but missed 
by gel testing can cause hemolytic transfusion reactions. 
Transfusion 2016;56:2973–9.
 12. Heaton D, McLoughin K. Jk(a–b–) RBCs resist urea lysis. 
Transfusion 1982;22:70–1.
Desiree Joy Anne M. Talabong, MD, MT(ASCP i)cm (corresponding 
author), Immunohematology Reference Technologist II, Immuno-
hematology Reference Laboratory, American Red Cross Biomedical 
Services, 2700 Southwest Freeway, Houston, TX 77098, desiree.
talabong@redcross.org; and Walter E. Kelley, DO, FCAP, Medical 
Director, Immunohematology Reference Laboratory, American Red 
Cross Biomedical Services, Houston, TX.
